Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Votrient in relapsed or refractory urothelial cancer
NCT01031875Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Dec 2009
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pazopanib in urothelial carcinoma (UC), bladder cancer, transitional cell carcinoma of the renal pelvis and ureter (TCC), urethral cancer, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Started Dec 2009; status: completed.
02
Drugs
pazopanib
03
Conditions
urothelial carcinoma (UC)bladder cancertransitional cell carcinoma of the renal pelvis and ureter (TCC)urethral cancer
Beyond the preview
Go deeper on NCT01031875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01031875.